Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.
Reasonable growth potential and fair value.
Share Price & News
How has Ironwood Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: I76's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: I76 underperformed the German Biotechs industry which returned -13.2% over the past year.
Return vs Market: I76 exceeded the German Market which returned -20.9% over the past year.
Price Volatility Vs. Market
How volatile is Ironwood Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Ironwood Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: I76 (€9.2) is trading below our estimate of fair value (€13.71)
Significantly Below Fair Value: I76 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: I76 is good value based on its PE Ratio (26.1x) compared to the Biotechs industry average (40.7x).
PE vs Market: I76 is poor value based on its PE Ratio (26.1x) compared to the German market (16.6x).
Price to Earnings Growth Ratio
PEG Ratio: I76 is poor value based on its PEG Ratio (1.5x)
Price to Book Ratio
PB vs Industry: I76 has negative assets, so we can't compare its PB Ratio to the DE Biotechs industry average.
How is Ironwood Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: I76's forecast earnings growth (17.5% per year) is above the savings rate (-0.4%).
Earnings vs Market: I76's earnings (17.5% per year) are forecast to grow faster than the German market (14.1% per year).
High Growth Earnings: I76's earnings are forecast to grow, but not significantly.
Revenue vs Market: I76's revenue (6.4% per year) is forecast to grow faster than the German market (3.9% per year).
High Growth Revenue: I76's revenue (6.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: I76's Return on Equity is forecast to be very high in 3 years time (61.9%).
How has Ironwood Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: I76 has a high level of non-cash earnings.
Growing Profit Margin: I76 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: I76 has become profitable over the past 5 years, growing earnings by 4.8% per year.
Accelerating Growth: I76 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: I76 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).
Return on Equity
High ROE: I76's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Ironwood Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: I76 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: I76 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: I76 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: I76's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Inventory Level: I76 has a low level of unsold assets or inventory.
Debt Coverage by Assets: I76 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: I76 is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: I76 is profitable, therefore cash runway is not a concern.
What is Ironwood Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate I76's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate I76's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if I76's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if I76's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of I76's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Mallon (56yo)
Mr. Mark Mallon has been chief executive officer at Ironwood Pharmaceuticals, Inc. since April 01, 2019 and serves as its Director and served as its Executive Senior Adviser since January 4, 2019. Mr. Ma ...
|CFO, Senior VP & Treasurer||no data||US$1.91m||0.037% $538.3k|
|CEO & Director||1yr||no data||0.0097% $139.8k|
|Co-Founder and Senior VP of R&D Strategy & External Innovation||3yrs||no data||no data|
|Co-Founder and VP of sGC R&D||22.25yrs||no data||no data|
|Chief Accounting Officer & VP of Finance||0.75yr||no data||0.043% $616.6k|
|Senior VP of Corporate Development & Chief Administrative Officer||no data||US$1.93m||0.068% $985.1k|
|Vice President of Investor Relations & Corporate Communications||no data||no data||no data|
|Senior Vice President of Human Resources||8.25yrs||no data||no data|
|Chief Development Officer & Senior VP of Global Development||3yrs||US$4.14k||no data|
Experienced Management: I76's management team is considered experienced (3 years average tenure).
|CEO & Director||1yr||no data||0.0097% $139.8k|
|Independent Director||5yrs||US$307.67k||0.037% $532.9k|
|Member of Pharmaceuticals Advisory Committee||no data||no data||no data|
|Independent Director||7.08yrs||US$311.42k||0.12% $1.7m|
|Independent Director||4yrs||US$301.42k||0.055% $795.3k|
|Member of Pharmaceutical Advisory Committee||3.17yrs||no data||no data|
|Independent Director||1yr||no data||0.016% $235.2k|
|Chairman of the Board||no data||US$311.42k||0.069% $1.0m|
|Independent Director||1yr||no data||0.016% $235.2k|
Experienced Board: I76's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.
Ironwood Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Ironwood Pharmaceuticals, Inc.
- Ticker: I76
- Exchange: DB
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.562b
- Listing Market Cap: US$1.447b
- Shares outstanding: 158.21m
- Website: https://www.ironwoodpharma.com
Number of Employees
- Ironwood Pharmaceuticals, Inc.
- 100 Summer Street
- Suite 2300
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IRWD||NasdaqGS (Nasdaq Global Select)||Yes||Class A Common Stock||US||USD||Feb 2010|
|I76||DB (Deutsche Boerse AG)||Yes||Class A Common Stock||DE||EUR||Feb 2010|
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the Canada and European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with GI diseases; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Boston, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/04 00:37|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.